



## GTG Q3 FY22 Business Update Webcast

**Melbourne, Australia, 14 April 2022:** Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to invite shareholders to participate in a business update webcast to be held on Thursday, 21 April 2022 (Wednesday, 20 April 2022 in New York), to present the quarterly results for the period ended 31 March 2022.

To register, please follow the link below.

Date: Thursday, 21 April 2022 (Wednesday, 20 April 2022 New York time)

Time: 8:00am AEST (6:00pm New York time)

Registration Link: <https://apac.onlinexperiences.com/Launch/QReg/ShowUUID=C072BAB2-197A-4944-8285-9081D418BF20>

Authorised for release by the Board of Genetic Technologies Limited

-END-

### Investor Relations (AUS)

Hugh Morgan

Market Eye

M: +61 407 453 109

E: [hugh.morgan@marketeye.com.au](mailto:hugh.morgan@marketeye.com.au)

### About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company’s Polygenic Risk Score (PRS) platform is a proprietary risk stratification platform developed over the past decade integrating clinical and genetic risk delivering actionable outcomes for physicians and individuals. Leading the world in risk prediction in Oncology, Cardiovascular and Metabolic diseases. Genetic Technologies continues to develop a pipeline of risk assessment products.

For more information, please visit [www.genetype.com](http://www.genetype.com)